During the recent session, Taysha Gene Therapies Inc (NASDAQ:TSHA)’s traded shares were 1.7 million, with the beta value of the company hitting 1.02. At the last check today, the stock’s price was $2.45, reflecting an intraday loss of -4.47% or -$0.12. The 52-week high for the TSHA share is $3.31, that puts it down -35.1 from that peak though still a striking 57.14% gain since the share price plummeted to a 52-week low of $1.05. The company’s market capitalization is $642.05M, and the average intraday trading volume over the past 10 days was 3.91 million shares, and the average trade volume was 3.68 million shares over the past three months.

Taysha Gene Therapies Inc (TSHA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.09. TSHA has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it.

Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information

Taysha Gene Therapies Inc (TSHA) registered a -4.47% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.47% in intraday trading to $2.45, hitting a weekly high. The stock’s 5-day price performance is -7.36%, and it has moved by -16.21% in 30 days. Based on these gigs, the overall price performance for the year is -39.08%. The short interest in Taysha Gene Therapies Inc (NASDAQ:TSHA) is 31.98 million shares and it means that shorts have 6.29 day(s) to cover.

The consensus price target of analysts on Wall Street is $8.5, which implies an increase of 71.18% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $44 respectively. As a result, TSHA is trading at a discount of -1695.92% off the target high and -104.08% off the low.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -63.99%. While earnings are projected to return 12.04% in 2025, the next five years will return 11.06% per annum.

TSHA Dividends

Taysha Gene Therapies Inc is due to release its next quarterly earnings on 2025-May-15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

The next largest institutional holding, with 18.8 million shares, is of RTW INVESTMENTS, LP’s that is approximately 8.075% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $42.11 million.